Clinical trial
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
NCT03673501 is registered in ClinicalTrials.gov with Deciphera Pharmaceuticals, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- February 8, 2019
- Completion date
- December 31, 2026
- Enrollment
- 453 (actual)
- Sites
- 121
Conditions
As the registry lists them; a condition with its own page is linked.